Biogen Inc. (NASDAQ:BIIB) Given Average Recommendation of “Hold” by Analysts

Shares of Biogen Inc. (NASDAQ:BIIB) have been assigned a consensus rating of “Hold” from the twenty-eight analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, fifteen have issued a hold recommendation and twelve have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $205.3077.

Several equities research analysts have issued reports on the stock. Wedbush raised their price objective on shares of Biogen from $178.00 to $187.00 and gave the stock a “neutral” rating in a research report on Monday, February 9th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Biogen in a research report on Monday, December 29th. Tudor Pickering set a $201.00 target price on Biogen in a research note on Monday, February 9th. HSBC lifted their price target on Biogen from $143.00 to $150.00 and gave the stock a “reduce” rating in a report on Tuesday, March 17th. Finally, Canaccord Genuity Group boosted their price target on Biogen from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Monday, February 9th.

Biogen Price Performance

NASDAQ:BIIB opened at $183.64 on Tuesday. The company has a market cap of $26.95 billion, a P/E ratio of 20.84, a P/E/G ratio of 1.44 and a beta of 0.15. The firm’s fifty day moving average price is $184.02 and its two-hundred day moving average price is $169.17. Biogen has a one year low of $110.04 and a one year high of $202.41. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03.

Biogen (NASDAQ:BIIB) last posted its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter last year, the company posted $3.44 EPS. Biogen’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities analysts expect that Biogen will post 15.83 earnings per share for the current year.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.18% of the company’s stock.

Institutional Trading of Biogen

Hedge funds and other institutional investors have recently bought and sold shares of the business. Empowered Funds LLC increased its holdings in shares of Biogen by 64.9% during the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after purchasing an additional 2,777 shares during the period. Focus Partners Wealth boosted its stake in shares of Biogen by 172.2% in the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after buying an additional 6,436 shares during the period. Sivia Capital Partners LLC acquired a new stake in Biogen during the second quarter worth approximately $216,000. Cetera Investment Advisers grew its position in Biogen by 2.2% during the second quarter. Cetera Investment Advisers now owns 12,888 shares of the biotechnology company’s stock worth $1,619,000 after buying an additional 280 shares in the last quarter. Finally, Handelsbanken Fonder AB increased its stake in Biogen by 21.6% during the 2nd quarter. Handelsbanken Fonder AB now owns 97,601 shares of the biotechnology company’s stock worth $12,258,000 after acquiring an additional 17,347 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.